Sunday, April 28, 2024
4/28/2024
7. Project Summary/Abstract Mycosis Fungoides/Cutaneous T Cell Lymphoma (MF/CTCL) is a rare, indolent Non-Hodgkin's Lymphoma (NHL), without a known cure, that presents as skin patches, plaques, tumors, or erythroderma with significant morbidity and impact on health-related quality of life (HR-QoL). Effective early treatment improves HR-QoL and may prevent disease progression. As per current NCCN guidelines, many skin-directed therapies (SDTs) are used for the treatment of early stage MF/CTCL including topicals, ultraviolet (UV) phototherapy, and radiation therapy. None have been FDA-approved for first-line therapy and most are used off-label. Given the chronic, recurrent nature of MF/CTCL, most patients require repeat courses of therapy and trying other therapies. The use of several SDTs are limited by skin irritation/dermatitis and long-term cumulative toxicity. Given this, there is an urgent need for additional SDTs for CTCL with fewer side effects. Topical hypericin is non-mutagenic, not systemically absorbed, activated by noncarcinogenic visible light, selectively taken up by tumor cells in the skin (up to 10-fold) and induces mitochondrial apoptosis. Phase 1, 2 and 3 clinical studies in MF/CTCL have demonstrated safety and efficacy. A recent multicenter, randomized, placebo-controlled, blinded Phase 3 study, enrolled 169 patients with Stage IA, IB or IIA CTCL and administered treatments twice weekly for at least 6 weeks (Cycle 1). In Cycle 1, 116 subjects received SGX301 to 3 index lesions with an overall response rate (ORR) of 16% compared to placebo ORR 4% (n=50, p=0.04). In Cycle 2 the ORR in patients receiving SGX301 for both cycles (12 weeks) was 40% (p<0.0001 vs placebo or 6 weeks of treatment). SGX301 treatment is safe and well tolerated, with potential favorable long-term safety given its mode of action. Although the trial showed efficacy, the dosing regimen was inflexible and short duration vs other skin-directed therapies where peak ORR can take 4-24 months of treatment. The current proposal will study SGX301 efficacy/safety utilizing a continuous treatment schedule for up to 1 year in an open label, multicenter clinical trial of 50 patients over 6 sites. The Specific Aims are: 1: Define optimal duration of SGX301 therapy to maximal ORR in early stage MF/CTCL patients on a “real world” treatment schedule up to 12 months. 2: Define safety profile during treatment. 3: Assess efficacy of SGX301 in disease subtypes and different skin lesions (patch vs plaque). 4: Assess genomic changes in skin/peripheral blood (utilizing high throughput sequencing [HTS-PCR] and targeted next generation sequencing [NGS]) and apoptosis markers (utilizing immunohistochemistry) as correlates of clinical response to SGX301 therapy.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
